Filing Flows › Xilio Therapeutics (XLO) › Q1 2026 › vs Q4 2025
Xilio Therapeutics (XLO) Q1 2026 vs Q4 2025 (quarter over quarter)
Xilio Therapeutics's revenue fell $1.0M (-8%) from $13.7M in Q4 2025 to $12.6M in Q1 2026.
Xilio Therapeutics, Q1 2026: revenue $12.6M (+332% year over year), operating margin -111.6%, net loss $9.5M, operating cash flow −$22.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $12.6M | $13.7M | −$1.0M | -8% |
| Other income, net | $4.6M | $22.2M | −$17.6M | -79% |
| Net loss | $9.5M | −$10.4M | $19.9M | — |
| Costs & expenses | $26.8M | $35.9M | −$9.1M | -25% |
| Operating costs | $26.8M | $25.5M | $1.2M | +5% |
| Research & development | $19.8M | $18.1M | $1.7M | +9% |
| General & admin | $6.9M | $7.4M | −$472K | -6% |
| Operating cash sources | $24.9M | $5.3M | $19.6M | +374% |
| Depreciation & amortization | $344K | $323K | $21K | +7% |
| Share-based compensation | $2.2M | $2.9M | −$719K | -25% |
| Cash used in operations | $22.3M | $2.0M | $20.3M | 11× |
| Net loss absorbed | $9.5M | −$10.4M | $19.9M | — |
| Working capital & other | $15.4M | $15.6M | −$242K | -2% |
Questions
How much did Xilio Therapeutics's revenue grow quarter over quarter in Q1 2026?
Xilio Therapeutics's revenue fell $1.0M (-8%) from $13.7M in Q4 2025 to $12.6M in Q1 2026.